Littérature scientifique sur le sujet « Guo min zheng fu »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Guo min zheng fu ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Guo min zheng fu"
1
Cai, Xiaobo, Min Cao, Huihui Guo, Qingliang Yang, Xiangfei Kong, Yong Du, Zhicang Ye et al. « Abstract 6581 : DX126-262 combined with chemotherapy (Cisplatin and 5-Fu) demonstrates promising antitumor efficacy in HER2-positive gastric cancer ». Cancer Research 84, no 6_Supplement (22 mars 2024) : 6581. http://dx.doi.org/10.1158/1538-7445.am2024-6581.
Texte intégralRésumé :
Abstract Gastric cancer is a common malignant tumor of the digestive system, and its morbidity and mortality rank among the top five in the world. Although significant progress has been made in cytotoxic chemotherapy, immunotherapy and targeted therapy in recent years, the long-term prognosis of patients with advanced or metastatic gastric cancer is still poor. Trastuzumab combined with chemotherapy is the first-line standard of care (SOC) for HER2-positive advanced or metastatic gastric cancer. Two ADC drugs targeting HER2, DS-8201 and RC-48, have also been approved for the treatment of gastric cancer. However, their limited clinical benefits and occurrence of adverse events still present a significant challenge. Therefore, minimizing the off-target toxicity and collateral damage while achieving significant chemotherapy efficacy has become the focus of gastric cancer treatment. DX126-262 is a novel HER2-targeting antibody-drug conjugate (ADC), generated by conjugating a Tubulysin B analogue to a recombinant humanized anti-HER2 monoclonal antibody through a linker containing branched hydrophilic polyethylene glycol, using thiol-maleimide chemistry to achieve drug antibody ratio (DAR) of 3.8. Previous studies have confirmed that DX126-262 monotherapy showed excellent efficacy in HER2-positive gastric cancer NCI-N87 cells in vitro and in vivo. And the efficacy has also been demonstrated in clinical trials (now in phase II, CTR20211871). Based on above results, we intended to further explore whether combination therapy of DX126-262 with Cisplatin and 5-FU can improve the anti-tumor efficacy compared with SOC (Herceptin plus Cisplatin and 5-FU) or DS-8201 monotherapy. The triple-drug combination therapy demonstrated much better therapeutic efficacy than single drug (DX126-262, Cisplatin, 5-FU, Herceptin, or DS-8201) or double-drug combination (Cisplatin plus 5-FU) or SOC (Herceptin plus Cisplatin and 5-FU) on human gastric cancer cells in vitro and in vivo. Meanwhile, triple-drug combination therapy did not exhibit superimposed toxicity, judging by the body weight of mice and hemal biochemistry assays. These results suggested that DX126-262 plus Cisplatin and 5-FU might be a promising strategy for treatment of HER2-positive advanced or metastatic gastric cancer in clinic. Citation Format: Xiaobo Cai, Min Cao, Huihui Guo, Qingliang Yang, Xiangfei Kong, Yong Du, Zhicang Ye, Zhixiang Guo, Lingli Zhang, Lu Bai, Junxiang Jia, Yunxia Zheng, Yongxiang Chen, Miaomiao Chen, Wei Zheng, Jun Zheng, Wenjun Li, Yuanyuan Huang, Mengmeng Liu, Zhongliang Fan, Hangbo Ye, Yifang Xu, Binbin Chen, Meng Dai, Robert Y. Zhao. DX126-262 combined with chemotherapy (Cisplatin and 5-Fu) demonstrates promising antitumor efficacy in HER2-positive gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6581.
2
Cai, Xiaobo, Min Cao, Huihui Guo, Qingliang Yang, Yongxiang Chen, Xiangfei Kong, Yong Du et al. « Abstract 1883 : A MUC1 antibody-conjugated with a tubulysin B analog, DXC005, demonstrates excellent synergistic effect in combination with gemcitabine for treatment of pancreatic tumors ». Cancer Research 84, no 6_Supplement (22 mars 2024) : 1883. http://dx.doi.org/10.1158/1538-7445.am2024-1883.
Texte intégralRésumé :
Abstract Pancreatic cancer is a malignant tumor with high incidence and mortality. It is difficult to diagnose and detect in the early stage, with low surgical resection rate and high recurrence and metastasis rate after surgery. At present, the clinical therapeutic strategy is extremely limited. The first-line Standard of Care (SOC) for unresectable pancreatic cancer is chemotherapy. The preferred regimen includes gemcitabine combined with albumin paclitaxel or FOLFIRINOX (5-FU+Oxaliplatin+Irinotecan). Due to the limited long-term benefits and toxic side effects of chemotherapy, targeted therapy combined with chemotherapy has become a new therapeutic strategy. MUC1 is a highly glycosylated transmembrane mucin located on the lumen surface of epithelial cells. It can protect cells from extreme factors and plays an important role in tumor cell metabolism, apoptosis, epithelial-mesenchymal transition (EMT) and metastasis. Previous studies have confirmed that MUC1 is highly expressed in a variety of tumors, including pancreatic cancer, and is closely related to poor prognosis. DXC005 is a novel MUC1-targeting antibody-drug conjugate (ADC), generated by conjugating a Tubulysin B analogue to a recombinant humanized anti-Muc1 monoclonal antibody. DXC005 is the first MUC1-ADC IND in China, and is currently in phase I clinical trials. Preclinical studies have confirmed the efficacy of DXC005 monotherapy (2.5 mg/kg, 5 mg/kg, 10 mg/kg in one administration) in the HuPrime ® pancreatic cancer PDX model (PA1194). The tumor growth inhibition (TGI) was 42.53 %, 70.77 %, and 95.58 %, respectively. We want to further clarify whether DXC005 combined with chemotherapeutic drug Gemcitabine can ensure or even improve the efficacy while reducing the dosage of Gemcitabine. In PA1194 xenograft model, DXC005 (3 mg/kg or 6 mg/kg) in combination with Gemcitabine (10 mg/kg) showed significant anti-tumor efficacy with 58.77% and 93.17% TGIs, respectively. In contrast, the treatment with 10 mg/kg of Gemcitabine alone exhibited much less TGI. Furthermore, complete response (CR) was observed in some animals after treatment with DXC005 (6 mg/kg) plus Gemcitabine (10 mg/kg). All groups of treatment are tolerated well, no abnormal animal behavior and body weight loss were observed in the study. The above results concluded that DXC005 combined with Gemcitabine can achieve synergistic effect even with reduced dose of Gemcitabine, which will serve as a support for synergistic application in clinical studies. Citation Format: Xiaobo Cai, Min Cao, Huihui Guo, Qingliang Yang, Yongxiang Chen, Xiangfei Kong, Yong Du, Zhicang Ye, Zhixiang Guo, Lingli Zhang, Lu Bai, Junxiang Jia, Yunxia Zheng, Wei Zheng, Jun Zheng, Wenjun Li, Yuanyuan Huang, Zhongliang Fan, Binbin Chen, Yanlei Yang, Meng Dai, Robert Y. Zhao. A MUC1 antibody-conjugated with a tubulysin B analog, DXC005, demonstrates excellent synergistic effect in combination with gemcitabine for treatment of pancreatic tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1883.
3
Zhenglang, Zhang. « 11. A Brief Discussion on Fu Hao ». Early China 9, S1 (1986) : 21–22. http://dx.doi.org/10.1017/s0362502800002984.
Texte intégralRésumé :
ABSTRACT(N.B. A version of this paper has now been published in Kaogu 1983.6:537-41.)Fu Hao (or Fu Zi ) appears in the oracle-bone inscriptions from Anyang. The name is often seen in Period I inscriptions (from the time of Wu Ding) and occasionally in Period IV inscriptions (from the time of Wu Yi and Wen Ding). The two are separated by four kings (Zu Geng, Zu Jia, Lin Xin, and Kang Ding), perhaps by as much as one hundred years. Does the Fu Hao in both periods refer to the same person? How can we explain this phenomenon?In the oracle-bone records of people and their activities there are cases where one figure is active in different periods. These names are often also place names, and these figures possess a populace and products. These names are probably what is termed “Clan-Territory titles” (a term found in the Gu shi kao, as quoted in the “Zheng yi” commentary to the Zuo zhuan). Based on their clan name they served hereditarily as officials. These clan names occur in historical literature, as in “In the past, our former kings were for generations Lords of Millet (Hou Ji ), serving under the Yü and Xia “(Guo yü “Zhou Yü” ); or “The Zhong and Li clans generation after generation ordered heaven and earth, … the Sima clan for generation after generation was in charge of the history of Zhou” (Shi ji, “Taishigong zixu” ).
4
Yu, Chen, et Zhang Shenghua. « The Rise and Fall of "Emperor" Zheng Min : The Case of the Zi Shen Guo ». Chinese Sociology & ; Anthropology 21, no 4 (juillet 1989) : 37–48. http://dx.doi.org/10.2753/csa0009-4625210437.
Texte intégral
5
Zhang, Qianpeng, Daquan Zhang, Xiaofei Sun, Beitao Ren et Zhiyong Fan. « (Invited, Digital Presentation) High-Efficiency and Stable Perovskite LEDs and Displays with Nanophotonic Methods ». ECS Meeting Abstracts MA2022-02, no 36 (9 octobre 2022) : 1308. http://dx.doi.org/10.1149/ma2022-02361308mtgabs.
Texte intégralRésumé :
Perovskite light-emitting diodes (PeLEDs) have experienced rapid development in the past 8 years. The external quantum efficiencies (EQEs) of red, green, and near-infrared (NIR) PeLEDs have all surpassed the 20% milestone. Meanwhile, the blue PeLEDs also achieved EQEs higher than 10% and are catching up quickly with PeLEDs of other colors. However, there are still two key problems remaining within the PeLEDs for their further development, namely the light extraction problem and the short lifetime problem. Therefore, in this report, we will discuss our recent work targeting addressing the above two critical problems. First, our work on improving the light extraction efficiency by deploying the nanophotonic substrates will be introduced. Second, the improvement of the device’s operational lifetime at high luminance conditions with perovskite nanowires embedded in a porous alumina template will be discussed. Third, a full evaporation method that is compatible with industrialization will be shown. Last but not least, our endeavors on the displays based on perovskite materials will be covered. References [1] Q. Zhang, M. M. Tavakoli, L. Gu, D. Zhang, L. Tang, Y. Gao, J. Guo, Y. Lin, S. -F. Leung, S. Poddar, Y. Fu, Z. Fan, "Efficient metal halide perovskite light-emitting diodes with significantly improved light extraction on nanophotonic substrates," Nature Communications, 10 (1), 727 (2019). [2] Q. Zhang, D. Zhang, L. Gu, S. Poddar, Y. Fu, L. Shu, and Z. Fan, “Three-dimensional perovskite nanophotonic wire array-based light-emitting diodes with significantly improved efficiency and stability,” ACS Nano, 14 (2), 1577-1585 (2020). [3] Y. Fu, Q. Zhang, D. Zhang, Y. Tang, L. Shu, Y. Zhu, and Z. Fan, “Scalable All-evaporation Fabrication of Efficient Light-Emitting Diodes with Hybrid 2D-3D Perovskite Nanostructures,” Advanced Functional Materials, 30, 2002913 (2020). [4] D. Zhang, Q. Zhang, B. Ren, Y. Zhu, M. Abdellah, Y. Fu, B. Cao, C. Wang, L. Gu, Y. Ding, K.-H. Tsui, S. Fan, S. Poddar, L. Shu, Y. Zhang, D.-B. Kuang, J.-F. Liao, Y. Lu, K. Zheng, Z. He, Z. Fan, “Large-scale Planar and Spherical Light-emitting Diodes Based on Arrays of Perovskite Quantum Wires”, Nature Photonics, 19, 284-290 (2022).
6
Zhu, Jingjing, Junxiang Jia, Huihui Guo, Xiangfei Kong, Yong Du, Zhicang Ye, Lingli Zhang et al. « Abstract 1882 : DXC024, a novel anti-TROP2/EGFR bispecific antibody and tubulysin conjugate, for targeted treatment of highly TROP2- or EGFR-expressing tumors ». Cancer Research 84, no 6_Supplement (22 mars 2024) : 1882. http://dx.doi.org/10.1158/1538-7445.am2024-1882.
Texte intégralRésumé :
Abstract Antibody drug conjugates (ADCs) which combine the precision of targeted therapy with the cytotoxic effects of chemotherapy have become a promising drug class in cancer therapy. Epidermal growth factor receptor (EGFR) is overexpressed in a wide diversity of epithelial tumors, promoting cell proliferation and survival pathways. Tumor-associated calcium signal transducer 2 (Trop2) is also expressed in a wide range of solid tumors and has been used as a transport gate for cytotoxic agents into cells in antibody-drug conjugate constructions for clinic applications. However, the approved Trop2 ADC, sacituzumab govitecan, only showed an objective response rate (ORR) of 17% and median OS of 9.5 months for lung cancers. In addition, both EGFR-ADC and Trop2-ADC had exhibited strong side effects in clinical trials due to their expression on some normal tissues, such as skin, mouth, eyes, etc. We generated bispecific Fab/scFv antibodies targeting both TROP2 and EGFR using the knob-into-hole technology, which presumably have wider efficacy, less on-target toxicity in comparison to the ADCs constructed based on the fully individual EGFR and Trop2 IgG antibodies having strong affinity to either EGFR or Trop2 antigens. Indeed, many of generated anti-TROP2/EGFR BsAbs showed strong binding activity in TROP2highEGFRhigh cells and demonstrated over 60% internalization rate within 60 min in vitro. The selected BsAbs were subsequently conjugated with tubulysin B analogs with varieties of peptidyl linkers to generate bispecific ADC (DXC024) candidates, two of which exhibited strong killing activity in A431, MDA-MB-468, Calu3, MCF-7 cells with IC50 of single to ten digital pM. In vivo, they showed very good durable antitumor response at dose as low as 4.6 mg/Kg for one injection in Calu3 (TROP2highEGFRmoderate) xenograft model, and demonstrated enhanced anti-tumor efficacy in comparison to those of the same payload conjugated to the monoclonal TROP2 or EGFR ADCs. These results indicated that DXC024 would be a promising ADC candidate for targeted treatment of highly either TROP2- or EGFR-expressing tumors. Citation Format: Jingjing Zhu, Junxiang Jia, Huihui Guo, Xiangfei Kong, Yong Du, Zhicang Ye, Lingli Zhang, Yongxiang Chen, Lu Bai, Yunxia Zheng, Wei Zheng, Jun Zheng, Juan Wang, Wenjun Li, Yuanyuan Huang, Zhongliang Fan, Mengmeng Liu, Binbin Chen, Meng Dai, Fang Du, Miaomiao Chen, Zhixiang Guo, Qingliang Yang, Robert Y. Zhao. DXC024, a novel anti-TROP2/EGFR bispecific antibody and tubulysin conjugate, for targeted treatment of highly TROP2- or EGFR-expressing tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1882.
7
Cai, Xiaobo, Min Cao, Huihui Guo, Qingliang Yang, Yongxiang Chen, Xiangfei Kong, Yong Du et al. « Abstract 4553 : DXC004A, a novel EGFR antibody-tubulysin analog conjugate demonstrated potential to broaden therapeutic opportunities for non-small cell lung cancer ». Cancer Research 84, no 6_Supplement (22 mars 2024) : 4553. http://dx.doi.org/10.1158/1538-7445.am2024-4553.
Texte intégralRésumé :
Abstract EGFR is a member of the epidermal growth factor receptor (HER) family, and the over-expression of EGFR plays an important role in the growth and progression of various tumors, including non-small cell lung cancer. Monoclonal EGFR antibodies, such as cetuximab and panitumumab, have proven efficacy in various types of cancer. However, treatment with the anti-EGFR agents can be associated with toxicities of the skin, nails, hair, and eyes. Nimotuzumab (Nimo) is the first humanized monoclonal antibody targeting EGFR and has been granted approval for use in squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal cancer in different countries. In contrast to cetuximab, Nimotuzumab is distinguished by achieving higher or similar complete remission rate (CRR) or overall remission rate (ORR) of the primary tumor in clinical applications but much less toxicity, resulting in a better safety profile, which has been attributed to its about 10-fold lower affinity. Paclitaxel combined with cisplatin is the first-line chemotherapy regimen for non-small cell lung cancer. A phase 2 clinical trial has confirmed that Nimotuzumab combined with concurrent chemoradiation therapy (radiation concurrent with docetaxel and cisplatin, CCRT) was well tolerated for locally advanced squamous cell lung cancer. However, the combination strategy of Nimo-CCRT has only demonstrated similar OS and PFS to those in the CCRT group. DXC004A is an ADC drug targeting EGFR, in which a Nimotuzumab derivative and a Tubulysin B analog is conjugated by a functional linker. DXC004A is in phase I clinical trial and has demonstrated clinical activity in advanced non-small cell lung cancers and good tolerability. In vitro and in vivo results had confirmed that DXC004A monotherapy had better anti-tumor activity than the combination of Nimotuzumab and Tubulysin analog in HCC827 cell lines with high EGFR expression. Meanwhile, a single injection of low-dose DXC004 (2.5 mg/kg) in HCC827 xenograft model showed very good durable anti-tumor effect. Moreover, the combination of DXC004A with Cisplatin exhibited significantly better activities than that of Nimo-CCRT combination, DXC004A or cisplatin alone, in vitro and in vivo, which might solve the predicament of poor efficacy of Nimo-CCRT combination therapy. This synergy results suggested that DXC004A plus cisplatin would possibly be a new adjuvant therapy for non-small cell lung cancer in further clinical studies. Citation Format: Xiaobo Cai, Min Cao, Huihui Guo, Qingliang Yang, Yongxiang Chen, Xiangfei Kong, Yong Du, Zhicang Ye, Zhixiang Guo, Lingli Zhang, Lu Bai, Junxiang Jia, Yunxia Zheng, Wei Zheng, Jun Zheng, Wenjun Li, Yuanyuan Huang, Zhongliang Fan, Binbin Chen, Meng Dai, Robert Y. Zhao. DXC004A, a novel EGFR antibody-tubulysin analog conjugate demonstrated potential to broaden therapeutic opportunities for non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4553.
8
Drewniak, Sabina Elżbieta, Roksana Muzyka et Łukasz Drewniak. « The structure of thermally reduced graphene oxide ». Photonics Letters of Poland 12, no 2 (1 juillet 2020) : 52. http://dx.doi.org/10.4302/plp.v12i2.1021.
Texte intégralRésumé :
The paper focused on the description of the reduced graphene oxide (rGO) structure. This material is obtained from a multistage production process. Each of these stages has a large impact on its structure (the number and type of functional groups, number of defect or the size of the flakes), and this in turn affects its properties. We would like to visualize the reduced graphene oxide, both using a diagram showing the atomic structure, as well as by imaging using scanning electron microscopy (SEM) and atomic force microscopy (AFM). In the paper, the elementary composition of selected elements and data obtained from X-ray photoelectron spectroscopy technique (XPS) will be also presented. Full Text: PDF ReferencesX. Peng, Y. Wu, N. Chen, Z. Zhu, J. Liu, and H. Wang, "Facile and highly efficient preparation of semi-transparent, patterned and large-sized reduced graphene oxide films by electrochemical reduction on indium tin oxide glass surface", Thin Solid Films 692, 137626 (2019). CrossRef L. Guo, Y.-W. Hao, P.-L. Li, J.-F. Song, R.-Z. Yang, X.-Y. Fu, S.-Y. Xie, J. Zhao and Y.-L. Zhang, "Improved NO2 Gas Sensing Properties of Graphene Oxide Reduced by Two-beam-laser Interference", Sci. Rep. 8, 1 (2018). CrossRef Y. S. Milovanov, V.A. Skryshevsky, , O.M. Slobodian, , D.O. Pustovyi, X.Tang, J.-P. Raskin, and A.N. Nazarov, "Influence of Gas Adsorption on the Impedance of Graphene Oxide", 2019 IEEE 39th Int. Conf. Electron. Nanotechnology, ELNANO 2019 - Proc. 8783946, CrossRef M. Reddeppa, B.-G. Park, , M.-D. Kim, K.R. Peta, N.D. Chinh, D. Kim, S.-G. Kim, and G. Murali, "H2, H2S gas sensing properties of rGO/GaN nanorods at room temperature: Effect of UV illumination", Sensors Actuators B. Chem. 264, (2018). CrossRef W. L. Xu, C. Ding, , M.-S. Niu, X.-Y. Yang, F. Zheng, J. Xiao, M. Zheng and X.-T. Hao, "Reduced graphene oxide assisted charge separation and serving as transport pathways in planar perovskite photodetector", Org. Electron. 81, 105663 (2020). CrossRef K. Sarkar, M. Hossain, P. Devi, K. D. M. Rao, and P. Kumar, "Self‐Powered and Broadband Photodetectors with GaN: Layered rGO Hybrid Heterojunction", Adv. Mater. Interfaces, 6, 20 (2019). CrossRef S. Pei and H. M. Cheng, "The reduction of graphene oxide", Carbon, 50, 9 (2012). CrossRef R. Muzyka, S. Drewniak, T. Pustelny, M. Chrubasik, and G. Gryglewicz, "Characterization of Graphite Oxide and Reduced Graphene Oxide Obtained from Different Graphite Precursors and Oxidized by Different Methods Using Raman Spectroscopy", Materials 11, 7 (2018). CrossRef M.-H. Tran and H. K. Jeong, "Influence of the Grain Size of Precursor Graphite on the Synthesis of Graphite Oxide", New Phys. Sae Mulli, 63, 2 (2013). CrossRef M.-H. Tran, C.-S. Yang, S. Yang, I.-J. Kim, and H. K. Jeong, "Influence of graphite size on the synthesis and reduction of graphite oxides", Curr. Appl. Phys., 14, SUPPL. 1 (2014). CrossRef N. Sharma, Y. Jain, , M. Kumari, R. Gupta, S.K. Sharma, K. Sachdev, "Synthesis and Characterization of Graphene Oxide (GO) and Reduced Graphene Oxide (rGO) for Gas Sensing Application", Macromol. Symp. 376, 1 (2017). CrossRef M. Wei, L. Qiao, , H. Zhang, S. Karakalos, K. Ma, Z. Fu, M.T. Swihart, G. Wu, "Engineering reduced graphene oxides with enhanced electrochemical properties through multiple-step reductions", Electrochim. Acta, 258 (2017). CrossRef S. Drewniak, M. Procek, R. Muzyka, T. Pustelny, "Comparison of Gas Sensing Properties of Reduced Graphene Oxide Obtained by Two Different Methods", Sensors, 20, 11 (2020). CrossRef L. Li, R.-D. Lv, S. -C. Liu, Z. D. Chen, J. Wang, Y.-G. Wang, W. Ren, "Using Reduced Graphene Oxide to Generate Q-Switched Pulses in Er-Doped Fiber Laser", Chinese Physics Letters, 35, 11 (2018) CrossRef
9
Sun, Hanli, Jiao Huang, Kai Zhan, Wanli Wu, Xianqing Tang, Min Liu, Shanshan Guo, Hongjun Zheng, Yingjie Huang et Shi Zhong. « Abstract 3598 : A new strategy for T cell therapy : T cells secreting TCR anti-CD3 bispecific T-cell engager ». Cancer Research 84, no 6_Supplement (22 mars 2024) : 3598. http://dx.doi.org/10.1158/1538-7445.am2024-3598.
Texte intégralRésumé :
Abstract TCR-engineered T (TCR-T) cells and TCR-anti-CD3 bispecific T-cell engagers (TCEs) are potent TCR-based therapeutic agents with distinct advantages and limitations in tumor treatment. TCR-T cells offer durable persistence within patients but necessitate personalized manufacturing and lack the capacity to harness bystander T cells. Conversely, TCEs are readily available as "off-the-shelf" products and can recruit bystander T cells, yet they exhibit a shorter lifespan. In our study, we sought to merge the merits of both approaches by engineering T cells to secrete a TCR-anti-CD3 TCE specific for alpha fetoprotein (AFP), a tumor-associated antigen abundantly expressed in hepatocellular carcinoma (HCC). We initially identified a TCR with specificity for the AFP158-166 peptide bound to HLA-A*02:01 and enhanced its affinity to picomolar via phage display. To facilitate efficient secretion by T cells, we adapted the high-affinity TCR to a single-chain format (scTCR) and fused it with a CD3-specific single-chain antibody fragment (scAFP-TCE). Our findings demonstrated that scAFP-TCE effectively redirected bystander T cells to engage in the lysis of HCC cells. Moreover, scAFP-TCE could be secreted by T cells transduced with lentiviral particles encoding the TCE gene. These transduced T cells exhibited potent antitumor activity both independently and by enlisting bystander T cells. This innovative T cell strategy, combining the bystander-recruiting ability of fusion proteins with the durable persistence seen in T cell therapy after a single infusion, presents a promising alternative to conventional TCR-based therapeutic agents. We anticipate that this novel approach may hold substantial potential for enhancing HCC treatment and expanding the scope of TCR-based immunotherapies. Citation Format: Hanli Sun, Jiao Huang, Kai Zhan, Wanli Wu, Xianqing Tang, Min Liu, Shanshan Guo, Hongjun Zheng, Yingjie Huang, Shi Zhong. A new strategy for T cell therapy: T cells secreting TCR anti-CD3 bispecific T-cell engager [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3598.
10
Yang, Qingliang, Yuanyuan Huang, Junxiang Jia, Huihui Guo, Lingli Zhang, You Zhou, Zhicang Ye et al. « Abstract 5821 : DXC008, a novel STEAP1 antibody-tubulysin analog conjugate with a function linker, demonstrates a potential to broaden therapeutic opportunities for prostate tumors ». Cancer Research 84, no 6_Supplement (22 mars 2024) : 5821. http://dx.doi.org/10.1158/1538-7445.am2024-5821.
Texte intégralRésumé :
Abstract Six-transmembrane epithelial antigen of the prostate 1 (STEAP1), is a cell surface protein frequently expressed in prostate cancer, with limited expression in non-prostate tissues. A Steap1 antibody called Vandortuzumab conjugated with MMAE (DSTP3086S) was in the clinical phase I trial for treating STEAP1-expressing metastatic castration-resistant prostate cancer and showed acceptable safety at 2.4 mg/kg once every 3 weeks. However, many patients are nonresponsive to DSTP3086S due to low target expression levels and common treatment-related AEs which were caused by MMAE payloads. DXC008 was generated through screening the therapeutical index in vitro of conjugates of an anti-Steap1 antibody with varieties of payloads of tubulysin B analogs through function peptide spacer linkers. The generated DXC008 exhibited not only good affinity for Steap1 but also moderate affinity for Prostate-specific membrane antigen (PSMA) which is as well specifically overexpressed in most prostate cancer with limited expression in normal tissue. DXC008 demonstrated couple tens to a hundred of picomolar concentration (pM) of potency against several prostate tumor cells and over 60% internalization rate within 90 min in vitro. And in vivo it showed very good durable antitumor response as low dose as 1 mg/kg one injection in both high and moderate of both Steap1 and PSMA expression xenograft models. Pharmacokinetic profiles of DXC008 were favorable and the safety of Maximal Tolerable Dose (MTD) was over 120 mg/kg in single injection in mice. DXC008 has been forward to NHP toxicity study and it has potential to be a good STEAP1/PSMA-targeting ADC with a wide therapeutic window for prostate cancers. Citation Format: Qingliang Yang, Yuanyuan Huang, Junxiang Jia, Huihui Guo, Lingli Zhang, You Zhou, Zhicang Ye, Hangbo Ye, Yifang Xu, WenJun Li, Zhiyu Zhao, Lingyao Zhao, Lu Bai, Jun Zheng, Robert Y. Zhao. DXC008, a novel STEAP1 antibody-tubulysin analog conjugate with a function linker, demonstrates a potential to broaden therapeutic opportunities for prostate tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5821.
Thèses sur le sujet "Guo min zheng fu"
1
Wong, Linda. « Zhongguo she hui zhu yi de she hui fu li min zheng fu li gong zuo yan jiu / ». Beijing : Zhongguo she hui ke xue chu ban she, 1995.
Trouver le texte intégral
2
Zhang, Shifei. « Shanghai ai zheng zi zhu zu zhi yan jiu zu yuan can yu, she hui zhi chi he she hui xue xi de zeng quan xiao guo / ». online access from Digital dissertation consortium, 2001. http://libweb.cityu.edu.hk/cgi-bin/er/db/ddcdiss.pl?3025931.
Texte intégral
3
GUO, MIN-ZHENG, et 郭明政. « GUO, MIN-ZHENG ». Thesis, 1985. http://ndltd.ncl.edu.tw/handle/63560180977937808252.
Texte intégral
4
H, Huang T., et 黃聰錫. « A Study on the Relation between Space Modules of Public House Living,lllustrated Statements with MIN-ZU,SL-WEL,GUO-MAO and FU-XING West ». Thesis, 1998. http://ndltd.ncl.edu.tw/handle/72339155841820056528.
Texte intégralRésumé :
碩士國立雲林科技大學
工業設計研究所
86
The purpose of this research is to study the relation between the ideal space distribution and user-friendly environment based on homogeneous living condition. From the view of behavior science and various representative space-designed behavior, the author try to evaluate the interation between the space module and the users by applying the corss-tabel comparison. The contect of the research focuses on room space with auxiliary of related community and interior public facilities. For instance, the plane mechanism and the units of space are discussed, the major representatives are "the lobby", "the hall way" and :the projective style". Conforming to the "house built for sale" policy, there are more plane mechanisms to be studied including flexible room design. Furthermore, the issue of rebuilding and alternating can be further investigated through the official management and system.
5
« 抗戰前「西南」的宣傳措施及抗日主張(1932-1936年) ». 2002. http://library.cuhk.edu.hk/record=b5895961.
Texte intégralRésumé :
何致遠."2002年8月"
論文 (哲學碩士)--香港中文大學, 2002.
附參考文獻.
附中英文提要.
"2002 nian 8 yue"
He Zhiyuan.
Lun wen (zhe xue shuo shi)--Xianggang Zhong wen da xue, 2002.
Fu can kao wen xian.
Fu Zhong Ying wen ti yao.
前言 --- p.01-05
Chapter 第一章： --- 西南執行部的政治宣傳措施 --- p.06-36
Chapter 第二章： --- 西南的抗曰言論一一環繞中國對日整體方針的討論 --- p.37-51
Chapter 第三章： --- 西南的抗日言論´ؤ´ؤ從九一八事變至長城抗戰 --- p.52-80
Chapter 第四章： --- 西南的抗日言論一一從塘沽善後談判至胡漢民逝世 --- p.81-100
總結 --- p.101-102
參考書目
Livres sur le sujet "Guo min zheng fu"
1
Lei, Mao, et Yuan Jicheng, dir. Wuhan guo min zheng fu shi. [Wuhan shi] : Hubei ren min chu ban she, 1986.
Trouver le texte intégral
2
Liu, Jizeng. Wuhan guo min zheng fu shi. 8e éd. [Wuhan shi] : Hubei ren min chu ban she, 1986.
Trouver le texte intégral
3
Guo min zheng fu shi hua. Beijing : She hui ke xue wen xian zhu ban she, 2000.
Trouver le texte intégral
4
Peng, Huai'en. Zhinghua min guo zheng fu yu zheng zhi. 8e éd. Taibei Shi : Feng yun lun tan chu ban she, 1997.
Trouver le texte intégral
5
Han'guo, Zhu, dir. Nanjing guo min zheng fu ji shi. [Hefei shi] : Anhui ren min chu ban she, 1993.
Trouver le texte intégral
6
Renyuan, Wan, Wang Xiaohua et Zhongguo di 2 li shi dang an guan., dir. Jiang Jieshi yu guo min zheng fu. Xianggang : Shang wu yin shu guan, 1994.
Trouver le texte intégral
7
Guo min zheng fu shou fu Taiwan yan jiu. Beijing : Zhonghua shu ju, 2013.
Trouver le texte intégral
8
Yang, Rumei. Guo min zheng fu cai zheng gai kuang lun. [Beijing : Beijing zhong xian tuo fang ke ji fa zhan you xian gong si, 2012.
Trouver le texte intégral
9
Guo min zheng fu cai zheng gai kuang lun. [Beijing : Beijing zhong xian tuo fang ke ji fa zhan you xian gong si, 2012.
Trouver le texte intégral
10
Guoming, Liu, dir. Zhonghua min guo guo min zheng fu jun zheng zhi guan ren wu zhi. Beijing : Chun qiu chu ban she, 1989.
Trouver le texte intégralActes de conférences sur le sujet "Guo min zheng fu"
1
Xiaozhi Wang and Neil Pegg, ISSC 2022 Editors. « Proceedings of the 21st International Ship and Offshore Structures Congress VOLUME 3 Discussions ». Dans 21st International Ship and Offshore Structures Congress Volume 3 Discussions. SNAME, 2022. http://dx.doi.org/10.5957/issc-2022-discussion-vol-3.
Texte intégralRésumé :
Committee I.1: Environment Alexander Babanin (Chair); Mariana Bernardino; Franz von Bock und Polach; Ricardo Campos,; Jun Ding; Sanne van Essen; Tomaso Gaggero; Maryam Haroutunian; Vanessa Katsardi; Alexander Nilva; Arttu Polojarvi; Erik Vanem; Jungyong Wang; Huidong Zhang; Tingyao Zhu Floor Discussers: Florian Sprenger; Carlos Guedes Soares; Henk den Besten Committee I.2: Loads Ole Andreas Hermundstad (Chair); Shuhong Chai; Guillaume de Hauteclocque; Sheng Dong; Chih-Chung Fang; Thomas B. Johannessen; Celso Morooka; Masayoshi Oka; Jasna Prpić-Oršić; Alessandro Sacchet; Mahmud Sazidy; Bahadir Ugurlu; Roberto Vettor; Peter Wellens Official Discusser: Hayden Marcollo Committee II-1: Quasi-Static Response James Underwood (Chair); Erick Alley; Jerolim Andrić Dario Boote; Zhen Gao; Ad Van Hoeve; Jasmin Jelovica; Yasumi Kawamura; Yooil Kim; Jian Hu Liu; Sime Malenica; Heikki Remes; Asokendu Samanta; Krzysztof Woloszyk; Deqing Yang Official Discusser: Prof. T. Yoshikwa Committee II.2: Dynamic Response Gaute Storhaug (Chair); Daniele Dessi; Sharad Dhavalikar; Ingo Drummen; Michael Holtmann; Young-Cheol Huh; Lorenzo Moro; Andre Paiva; Svein Sævik; Rong-Juin Shyu; Shan Wang; Sue Wang; WenWei Wu; Yasuhira Yamada; Guiyong Zhang Floor Discussers: Ling Zhu; Tomoki Takami; Anriette (Annie) Bekker; Bruce Quinton; Robert Sielski Committee III.1: Ultimate Strength Paul E. Hess (Chair); Chen An; Lars Brubak; Xiao Chen; Jinn Tong Chiu; Jurek Czujko; Ionel Darie; Guoqing Feng; Marco Gaiotti; Beom Seon Jang; Adnan Kefal; Sukron Makmun; Jonas Ringsberg; Jani Romanoff; Saad Saad-Eldeen; Ingrid Schipperen; Kristjan Tabri; Yikun Wang; Daisuke Yanagihara Official Discusser: Jørgen Amdahl Committee III.2: Fatigue and Fracture Yordan Garbatov (Chair); Sigmund K Ås; Henk Den Besten; Philipp Haselbach; Adrian Kahl; Dale Karr; Myung Hyun Kim; Junjie Liu; Marcelo Igor Lourenço de Souza; Wengang Mao; Eeva Mikkola; Naoki Osawa; Fredhi Agung Prasetyo; Mauro Sicchiero; Suhas Vhanmane; Marta Vicente del Amo; Jingxia Yue Official Discusser Weicheng Cui Floor Discussers: Robert Sielski; Sören Ehlers; Stephane Paboeuf; Teresa Magoga Committee IV.1: Design Principles and Criteria Matthew Collette (Chair); Piero Caridis; Petar Georgiev; Torfinn Hørte; Han Koo Jeong; Rafet emek Kurt; Igor Ilnytskiy; Tetsuo Okada; Charles Randall; Zbigniew Sekulski; Matteo Sidari; Zhihu Zhan; Ling Zhu Official Discusser: Enrico Rizzuto Committee IV.2: Design Methods Andrea Ivaldi (Chair); Abbas Bayatfar; Jean-David Caprace; Gennadiy Egorov; Svein Erling Heggelund; Shinichi Hirakawa; Jung Min Kwon; Dan Mcgreer; Pero Prebeg; Robert Sielski; Mark Slagmolen; Adam Sobey; Wenyong Tang; Jiameng Wu Official Discusser: Mario Dogliani Committee V.1: Accidental Limit States Bruce Quinton; Gaetano De Luca; Topan Firmandha; Mihkel Körgesaar; Hervé Le Sourne; Ken Nahshon; Gabriele Notaro; Kourosh Parsa; Smiljko Rudan; Katsuyuki Suzuki; Osiris Valdez Banda; CareyWalters; Deyu Wang; Zhaolong Yu Official Discusser: Manolis Samuelides Committee V.2: Experimental Methods Sören Ehlers (Chair); Nagi Abdussamie; Kim Branner; ShiXiao Fu; Martijn Hoogeland; Kari Kolari; Paul Lara; Constantine Michailides; Hideaki Murayama; Cesare Rizzo; Jung Kwan Seo; Patrick Kaeding Official Discusser: Giles Thomas Committee V.3: Materials and Fabrication Technology Lennart Josefson (Chair); Konstantinos Anyfantis; Bianca de Carvalho Pinheiro; Bai-Qiao Chen; Pingsha Dong; Nicole Ferrari; Koji Gotoh; James Huang; Matthias Krause; Kun Liu; Stephane Paboeuf; Stephen van Duin; Fang Wang; Albert Zamarin Official Discusser: Frank Roland Floor Discussers Alessandro Caleo; Agnes Marie Horn; Krzysztof Woloszyk; Robert Sielski Committee V.4: Offshore Renewable Energy Atanasios Kolios (Chair); Kyong-Hwan Kim; Chen Hsing Cheng; Elif Oguz; Pablo Morato; Freeman Ralph; Chuang Fang; Chunyan Ji; Marc Le Boulluec; Thomas Choisnet; Luca Greco; Tomoaki Utsunomiya; Kourosh Rezanejad; Charles Rawson; Jose Miguel Rodrigues Official Discusser: Amy Robertson Committee V.5: Special Vessels Darren Truelock (Chair); Jason Lavroff; Dustin Pearson; Zbigniew (Jan) Czaban; Hanbing Luo; Fuhua Wang; Ivan Catipovic; Ermina Begovic; Yukichi Takaoka; Claudia Loureiro; Chang Yong Song; Esther Garcia; Alexander Egorov; Jean-Baptiste Souppez; Pradeep Sensharma; Rachel Nicholls-Lee Official Discusser: Jaye Falls Floor Discussers: Jasmin Jelovica; Stephane Paboeuf; Sören Ehlers Committee V.6: Ocean Space Utilization Sebastian Schreier (Chair); Felice Arena; Harry Bingham; Nuno Fonseca; Zhiqiang Hu; Debabrata Karmakar; Ekaterina Kim; Hui Li; Pengfei Liu; Motohiko Murai; Spiro J Pahos; Chao Tian; George Wang Official Discusser: Hideyuki Suzuki Floor Discussers: Robert Sielski; Sue Wang; Sarat Mohapatra; Gaute Storhaug; Henk den Besten Committee V.7: Structural Longevity Iraklis Lazakis (Chair); Bernt Leira; Nianzhong Chen; Geovana Drumond; Chi-Fang Lee; Paul Jurisic; Bin Liu; Alysson Mondoro; Pooria Pahlavan; Xinghua Shi; Ha Cheol Song; Tadashi Sugimura; Christian Jochum; Tommaso Coppola Official Discusser: Timo de Beer Floor Discusser: Krzysztof Woloszyk Committee V.8: Subsea Technology Agnes Marie Horn (Chair); Tauhid Rahman; Ilson Pasqualino; Menglan Duan; Zhuang Kang; Michael Rye Andersen; Yoshihiro Konno; Chunsik Shim; Angelo Teixeira; Selda Oterkus; Blair Thornton; Brajendra Mishra Official Discusser: Segen F. Estefen
2
Zhou, Jun, Xudong Zhang et Linbo Zhou. « Experimental Study on Improving the Fracture Conductivity of Acid Etched Fracture for Ultra-Deep and High Stress Carbonate Reservoirs ». Dans 57th U.S. Rock Mechanics/Geomechanics Symposium. ARMA, 2023. http://dx.doi.org/10.56952/arma-2023-0176.
Texte intégralRésumé :
ABSTRACT With the development of carbonate reservoirs moves to the ultra-deep layer, the etched fracture would be closes quickly in the high stress. In this paper, high channel sanding method with acid fracturing technology are combined, the strength and spread ways of the different type proppant are optimized, and the fracture conductivity of continuous sanding and channel sanding are tested. The experiment result shows that high strength ceramic proppant can improve the conductivity of acid erosion fractures under high pressure. In the stress of 50MPa, fracture conductivity by high channel sanding with 86MPa ceramic could be increased by more than 51% than that of conventional acid etched fracture. The flow conductivity increase amplitude reaches more than 700% in the condition of 90MPa. By changing the sanding mode, the quantity of proppant can be saved, the pump risk can be reduced, and the stable and solid support channel can also be formed to improve the conductivity of acid etched fractures in ultra-deep carbonate reservoirs. INTRODUCTION With the gradual development of the Carbonate reservoir to the ultra-deep layer, the depth of the reservoir has reached 8,800 meters, and the temperature has been raised from 120°C to 180°C. The increase of reservoir depth and temperature brings many new challenges to reservoir stimulation. When the effective closure stress of the reservoir increases from 10 MPa to 55 MPa, the conventional acid etched fracture conductivity decreases by 95% (Yao et al., 2015). With the increase of closure stress, the insufficient support strength is the main reason for the rapid decrease of the fracture conductivity. In order to increase the fracture validity period after acid fracturing, the main objective is to improve the long-term etched fracture conductivity. The existing acid fracturing is to dissolve calcareous minerals on the fracture surface, leaving the unreacted rock skeleton as the supporting point. Due to the uneven distribution of each point and its low compressive resistance, it will be crushed gradually under high closure stress. Many scholars (Yi et al., 2006, 2008, 2010, Gao et al., 2015, Wang et al., 2012,2016, He et al., 2014) tried to improve the fracture conductivity by using cross-linked acid carrying sand or compound acid fracturing, and achieved certain effect in the oilfield application. However, with the increase of reservoir depth, it becomes more and more difficult to add sand into the carbonate reservoirs. In the meantime, proppant concentration cannot be effectively increased, making it difficult to achieve the effect of high concentration proppant placement (Zhuang et al., 2014). In recent years, many researchers try to use high channel pulse sand-adding method in low permeability reservoir (Zhong et al., 2012, Wu et al., 2014, Liu, 2015, Fu et al., 2016).